OGEN - Oragenics, Inc. Annual Revenue Growth (Last Twelve Months)

This TTM annual sales growth chart illustrates the dynamics of Oragenics, Inc. (OGEN). The creation of vaccines for mandatory programs provides the company with a stable cash flow. The development of the ONP-002 drug for brain injury therapy is attracting attention from the military and athletes. Meanwhile, 0.00 records a new level, highlighting the venture status of the asset, which relies on the brand's high scientific reputation.
Summary analytical data breakdowns for Oragenics Inc. (OGEN)

The assessment of business resilience is based on an analysis of revenue growth rates over the last twelve months, which allows for the elimination of seasonal fluctuations and the identification of the actual demand vector. The TTM annual sales growth trend reflects the monetization efficiency of the Oragenics, Inc. (OGEN) patent portfolio, confirming the extent to which medical centers depend on the company's exclusive supplies of biopharmaceutical products.